At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 98 enrolled
Drug / intervention
2% sodium chondroitin sulfate +1 moredrug
Likely dose
2% sodium chondroitin sulfate 20 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Randomized, Double-Blind, Parallel Group Evaluation of the Effectiveness and Safety of Uracyst® Compared to Inactive Control in Subjects With Interstitial Cystitis/Painful Bladder Syndrome
In Brief
A Phase 2 clinical trial evaluating 2% sodium chondroitin sulfate and Placebo for Interstitial Cystitis and Painful Bladder Syndrome. Completed, enrolled 98 participants across 20 sites.
Detailed Summary
A new device for interstitial cystitis is compared to inactive control to determine if it is safe and effective. The study lasts approximately 7 weeks with a 19-week follow-up period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInterstitial Cystitis, Painful Bladder Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2009
Enrollment StartJul 2009
Primary CompletionDec 2010
TodayJul 2026
First PostedJun 12, 2009
Enrollment StartJul 1, 2009
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.1 years ago
Interventions
2% sodium chondroitin sulfatedrug
Weekly 20 mL Intravesical instillation
Placebodrug
The identical buffer used in Uracyst for the same administration